Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Introduction

Duchenne Muscular Dystrophy is a significant neurodegenerative disorder affecting millions worldwide. This page provides comprehensive information about the disease, including its mechanisms, symptoms, diagnosis, and treatment approaches.

Overview

Duchenne Muscular Dystrophy (DMD) is the most common and severe form of childhood muscular dystrophy, affecting approximately 1 in 3,500-5,000 live male births [1]. It is an X-linked recessive disorder caused by mutations in the DMD gene that result in the absence or severe reduction of functional dystrophin protein, leading to progressive muscle degeneration, loss of ambulation, and premature death [2]. [@machine]

Genetics and Molecular Biology

DMD Gene

The DMD gene is one of the largest known human genes, spanning over 2.2 megabases on chromosome Xp21.1. It encodes dystrophin, a critical cytoskeletal protein that provides structural stability to muscle cell membranes [3]. [@effects]

Types of Mutations

• Frameshift/nonsense mutations: ~60-70% of cases, cause premature stop codons
• Large deletions: ~60-70% of cases, typically involve one or more exons
• Duplications: ~10-15% of cases
• Small mutations: ~20-25% of cases (missense, splice site, small deletions)

Dystrophin Protein

...

Duchenne Muscular Dystrophy

Introduction

Duchenne Muscular Dystrophy is a significant neurodegenerative disorder affecting millions worldwide. This page provides comprehensive information about the disease, including its mechanisms, symptoms, diagnosis, and treatment approaches.

Overview

Duchenne Muscular Dystrophy (DMD) is the most common and severe form of childhood muscular dystrophy, affecting approximately 1 in 3,500-5,000 live male births [1]. It is an X-linked recessive disorder caused by mutations in the DMD gene that result in the absence or severe reduction of functional dystrophin protein, leading to progressive muscle degeneration, loss of ambulation, and premature death [2]. [@machine]

Genetics and Molecular Biology

DMD Gene

The DMD gene is one of the largest known human genes, spanning over 2.2 megabases on chromosome Xp21.1. It encodes dystrophin, a critical cytoskeletal protein that provides structural stability to muscle cell membranes [3]. [@effects]

Types of Mutations

• Frameshift/nonsense mutations: ~60-70% of cases, cause premature stop codons
• Large deletions: ~60-70% of cases, typically involve one or more exons
• Duplications: ~10-15% of cases
• Small mutations: ~20-25% of cases (missense, splice site, small deletions)

Dystrophin Protein

Dystrophin (427 kDa) is a rod-shaped cytoplasmic protein that: [@screening]

• Connects the actin cytoskeleton to the dystrophin-associated glycoprotein complex (DGC)
• Stabilizes muscle cell membranes during contraction
• Prevents membrane damage from mechanical stress
• Has multiple neuronal isoforms (Dp140, Dp71) important for cognitive function

Disease Mechanism Flowchart

Pathophysiology

Primary Mechanism

The absence of functional dystrophin leads to: [@twoyear]

Membrane fragility: Mechanical stress causes sarcolemmal tears

Calcium dysregulation: Influx through damaged membranes triggers proteolysis

Oxidative stress: Mitochondrial dysfunction increases [reactive oxygen species](/entities/reactive-oxygen-species)

Inflammation: Immune cell infiltration accelerates muscle damage

Fibrosis: Replacement of muscle with adipose and connective tissue

Secondary Mechanisms

• Sarcolemmal dysfunction: Reduced neuronal nitric oxide synthase (nNOS) localization
• Mitochondrial abnormalities: Energy production deficits
• [Autophagy](/entities/autophagy) impairment: Accumulation of damaged proteins and organelles
• Satellite cell exhaustion: Impaired muscle regeneration capacity

Clinical Features

Age of Onset and Progression

Infancy (0-2 years):

• Hypotonia, motor delay
• Delayed sitting, walking
• Calf pseudohypertrophy
• Gower's sign (using hands to climb up legs when rising)

Early Childhood (3-5 years):

• Progressive proximal weakness
• Waddling gait
• Difficulty climbing stairs
• Frequent falls

Late Childhood (6-12 years):

• Loss of running ability
• Progressive scoliosis
• Cardiomyopathy onset (usually by age 10)
• Respiratory function decline

Adolescence (13+ years):

• Loss of ambulation (typically by age 12-15)
• Severe scoliosis requiring surgical intervention
• Cardiomyopathy progression
• Respiratory insufficiency requiring support

Cardiac Involvement

• Dilated cardiomyopathy develops in nearly all patients
• Cardiac MRI shows early changes before symptoms
• Arrhythmias are common
• Requires aggressive monitoring and treatment

Cognitive and Behavioral

• Learning disabilities in ~30% of patients
• Intellectual disability in ~20%
• Attention deficit hyperactivity disorder (ADHD)
• Autism spectrum disorders more prevalent
• Executive function deficits

Diagnosis

Clinical Diagnosis

• Physical examination: Characteristic pattern of weakness
• Gower's sign: Pathognomonic for proximal muscle weakness
• Calf pseudohypertrophy: Due to fatty infiltration

Laboratory Findings

• Creatine kinase (CK): Extremely elevated (10-100x normal)
• Aldolase: Elevated
• Electromyography: Myopathic changes

Genetic Testing

• Multiplex ligation-dependent probe amplification (MLPA): Detects deletions/duplications
• Next-generation sequencing (NGS): Identifies small mutations
• Carrier testing: Important for family planning

Muscle Biopsy

• Historical gold standard
• Shows absence of dystrophin (immunohistochemistry)
• Replaced by genetic testing in most cases

Management

Disease-Modifying Therapies

Corticosteroids (Standard of Care):

• Prednisone/prednisolone: 0.75 mg/kg/day
• Deflazacort: 0.9 mg/kg/day
• Benefits: Slows disease progression, prolongs ambulation
• Side effects: Weight gain, osteoporosis, cataracts, adrenal suppression

Exon Skipping Therapies:

• Exondys 51 (eteplirsen): Targets exon 51 skipping (~13% of patients)
• Vyondys 53 (golodirsen): Targets exon 53 (~8% of patients)
• Viltepso (viltolarsen): Targets exon 53 (Japan)
• Amondys 45 (casimersen): Targets exon 45 (~8% of patients)

Gene Therapy:

• Elevidys (SRP-9001, micro-dystrophin): AAV-mediated delivery
• FDA-approved for patients ages 4-5 (2023)
• Shows functional improvement in clinical trials
• Requires careful patient selection and monitoring

Supportive Care

Physical Therapy:

• Stretching routines to prevent contractures
• Gentle exercise to maintain function
• Assistive devices as needed

Cardiac Management:

• ACE inhibitors or ARBs: Cardiac protection
• Beta-blockers: For cardiomyopathy
• Pacemakers: For conduction abnormalities
• Regular echocardiograms and ECGs

Respiratory Care:

• Pulmonary function monitoring (FVC, FEV1)
• Non-invasive ventilation (BiPAP) when needed
• Cough assist devices
• Secretion clearance techniques

Orthopedic Management:

• Scoliosis monitoring and surgery
• Night-time orthoses to prevent contractures
• Physical therapy

Nutritional Support:

• Calorie-dense diets to maintain weight
• Calcium and vitamin D supplementation
• Monitoring for dysphagia

Emerging Therapies

• Utrophin modulators: Upregulation of utrophin as dystrophin substitute
• Myostatin inhibitors: Blocking muscle growth inhibitors
• Stem cell therapy: Various approaches in development
• CRISPR-based gene editing: Preclinical and early clinical stages

Prognosis

• Mean life expectancy: Early 30s (historically late teens)
• Current improvements: Many patients now living into 40s-50s with modern care
• Leading causes of death: Respiratory failure, cardiomyopathy
• Quality of life: Significantly improved with multidisciplinary care

Background

The study of Duchenne Muscular Dystrophy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Cardiac and skeletal muscle delivery of biotherapeutics with a blood vessel epicardial substance-targeting peptide.](https://pubmed.ncbi.nlm.nih.gov/41506143/) (2026 Jun) - Biomaterials
• [Machine learning for site risk prediction in clinical trials: development, external validation, and operational application in site qualification.](https://pubmed.ncbi.nlm.nih.gov/41741318/) (2026 May) - International journal of medical informatics
• [Effects of Bisphosphonates on Bone Micro-Architecture of Children With Duchenne Muscular Dystrophy: A Prospective Comparative Study.](https://pubmed.ncbi.nlm.nih.gov/41749413/) (2026 Apr) - Journal of cachexia, sarcopenia and muscle
• [Screening for brain-related comorbidities in Duchenne muscular dystrophy: Construction, reliability, and validity of the BIND screener.](https://pubmed.ncbi.nlm.nih.gov/41645051/) (2026 Apr) - Developmental medicine and child neurology
• [Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.](https://pubmed.ncbi.nlm.nih.gov/41518520/) (2026 Apr) - Neurology and therapy

References

• Dystrophin- Muscular Dystrophy Overview
• Becker Muscular Dystrophy

External Links

• [Parent- [ClinicalT